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1. Introduction
Direct repair is defined as the elimination of DNA and RNA damage using chemical rever‐
sion that does not require a nucleotide template, breakage of the phosphodiester backbone
or DNA synthesis. As such, the process of direct repair is completely error-free, granting a
major advantage in preservation of genetic information. In mammalian cells, direct repair is
utilized to repair specific types of DNA and RNA damage caused by ubiquitous alkylating
agents. Only two major types of proteins conduct direct repair in mammalian cells, O6-
methylguanine-DNA methyltransferase (MGMT or AGT) and ALKBH family Fe(II)/α-keto‐
glutarate dioxygenases (FeKGDs). In humans and mice, a single direct repair
methyltransferase protein exists, MGMT. In contrast, ALKBH FeKGDs represent a family of
nine homologs with conserved active site domains. Although the biochemical function of a
number of ALKBH proteins and their biological roles require further investigation, several
directly repair alkylation damage in DNA and RNA at base-pairing sites.
2. Direct repair substrates—DNA and RNA alkylation damage
Exposure to alkylating agents is  major cause of DNA and RNA damage, generating ad‐
ducts that can compromise genomic integrity. As a result, repair of alkylation adducts is
mediated by a variety of DNA repair pathways, some with overlapping substrate specif‐
icity.  However,  direct  DNA  repair  proteins  utilize  unique  mechanisms  to  specifically
eliminate damage at  base-pairing sites.  The frequency and site  of  DNA and RNA dam‐
age occurrence is dependent on the source and type of alkylating agent exposure, as dis‐
cussed in this section.
© 2013 Nay and O‘Connor; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
3. Sources of alkylation damage
Alkylating agents are present environmentally and also generated within the cell via oxida‐
tive metabolism. They modify DNA and RNA, forming adducts that disrupt replication and
transcription, trigger cell cycle checkpoints, and/or initiate apoptosis. If left unrepaired,
some adducts formed by alkylation damage can be cytotoxic and/or mutagenic [1-3].
Environmental alkylating agents fall into two primary groups, nitrosoureas that generate pri‐
marily O-alkylations and methanesulfonates that cause mostly N-alkylations [1, 3] (Figure 1).
These exogenous alkylating agents are present in air, water, plants and food, in the form of ni‐
trosamines, chloro- and bromomethane gases, myosamines and halocarbons [4]. There are also
industrially produced alkylating agents, including various chemotherapeutic agents [5, 6].
Figure 1. Examples of nitrosourea and methanesulfonate alkylating agents. (A) Nitrosourea, SN1, alkylating agents.
Abbrevations are as follows: methylnitrosourea (MNU); ethylnitrosourea (ENU); 1,3-bis (2chloroethyl)-1-nitrosourea
(BCNU); N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea- (CCNU); N-methyl-N-nitro-N-nitrosoguanidine (MNNG); N-eth‐
yl-N-nitro-N-nitrosoguanidine (ENNG). (B) Methanesulfonate, SN2, alkylating agents. Abbrevations are as follows: di‐
methylsufate (DMS); diethylsulfate (DES); methylmethanesulfonate (MMS); ethylmethanesulfonate (EMS). [14]
Enzymes involved in cellular metabolism are responsible for the majority of endogenous al‐
kylating agent damage. Nitrosating agents are generated, resulting in amine nitrosation, and
reactive oxygen species (ROS), which cause lipoperoxidation [7]. Additionally, a family of S-
adenosyl methionine (SAM) methyltransferase enzymes is involved in more than 40 meta‐
bolic reactions using SAM as a methyl donor to modify nucleic acids, proteins and lipids [8,
9]. Four of those SAM methyltransferase enzymes participate in DNA and RNA modifica‐
tion in mammalian cells. DNMT1, DNMT3A, and DNMT3B catalyze methyl group transfer
at the C5 position of cytosine in DNA CpG sequences [10], whereas TRDMT1 (DNMT2)
methylates the C5 position of cytosine 38 in aspartic acid tRNA [11].
3.1. Types of alkylating agents
Alkylating agents can be categorized by their method of activation. Some alkylating agents re‐
act directly with DNA and do not require any activation, whereas many alkylating agents, in‐
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cluding many carcinogens, must undergo metabolic activation by the cytochrome P450 system
to generate reactive species capable of modifying DNA [3, 12, 13]. In addition, alkylating agents
are electrophilic compounds that possess either one or two reactive groups that can interact
with the nucleophilic centers of DNA and RNA bases. Alkylating agents that can only react with
one nucleophilic center are mono-functional, whereas bi-functional agents can react with two
sites in DNA or RNA [1, 13]. Alkylating agents that are mono-functional primarily transfer alkyl
groups to ring nitrogens, while agents that react in a bi-functional manner not only react with
ring nitrogens, but can form cyclized DNA bases, by reacting with exocylic nitrogen and oxygen
groups [13] (Figure 2). In addition to methylating agents, larger alkylating agents also modify
nucleic acids—bi-functional ethylating agents can form exocyclic ethano and etheno adducts at
nitrogen and oxygen molecules in all DNA and RNA bases. Additionally, bi-functional alkylat‐
ing agents can produce DNA inter- and/or intrastrand cross-links [13]. Some alkylating agents
also react at phosphate residues to generate phosphotriesters, leading to potential single-strand
breaks [13] (Figure 2). Two main pathways, characterized as SN1 or SN2, are defined based on the
kinetics of the alkylation reaction, leading to the above mentioned modifications of DNA and
RNA bases [2].
Figure 2. (A) Purple arrows indicate sites in DNA most often methylated by SN1 alkylating agents. Green arrows indi‐
cate sites commonly modified by SN2 alkylating agents, orange arrows indicate sites in single-stranded DNA. Blue ar‐
rows indicate exocyclic amino groups important in formation of cyclized DNA adducts. The location of the major and
minor grooves in DNA are indicated. “R” is the attachment of the base to the deoxyribose and phosphodiester back‐
bone. (B) Modified phosphodiester isoforms in the DNA backbone. SN1 alkylating agents generally form more phos‐
photriester products than SN2 agents. [2,14]
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SN1 agents act via a two step reaction involving a unimolecular nucleophilic substitution
with a rate-limiting step that generates an intermediate carbonium ion electrophile that re‐
acts with nucleophilic DNA sites. Thus, the reaction kinetics depend only on the formation
of the carbonium ion intermediate (first-order). The triganol planar conformation of the sp2
hybridized carbon generated in the carbocation intermediate permits nucleophilic attack
from either side, yielding a racemic mixture of reaction products at chiral centers [13] (Fig‐
ure 3). Though agents that react via an SN1 mechanism produce both N- and O-alkylations,
increased amounts of modified oxygens are generated, compared to agents that react via an
SN2 mechanism.
Figure 3. SN1 and SN2 nucleophilic substitution reactions. (A) Example of an SN1 reaction. SN1 reactions are dependent
on formation of a carbonium ion intermediate that rate-limiting. Product chiral centres are a racemic mixture because
the intermediate can be attacked by either side. (B) Example of an SN2 reaction. Both reactants are required and there
is direct attack by the nuclephile in SN2 reactions. Chirality is maintained since a transition state is formed with the
chiral center. [2,14]
In contrast,  SN2 reaction mechanisms depend on both the alkylating agent and its target
to  define  the  kinetics  (second-order).  Using a  one  step reaction where  both  the  electro‐
phile and nucleophile are involved in the transition state,  SN2 alkylating agents proceed
with direct attack by the nucleophile on an electron deficient center. The nucleophile at‐
tacks from the back of the electrophile, forming the carbon-nucleophile bond and break‐
ing  the  carbon-leaving  group  bond.  Simultaneous  backside,  nucleophilic  attack  and
leaving group departure cause the incoming group to replace the leaving group. Because
a  transition  state  is  formed with  the  chiral  center,  chirality  is  maintained,  leading  to  a
stereocenter (inversion) configuration [13]  (Figure 3).  Alkylating agents that  react  via an
SN2 mechanism cause primarily N-alkylations.
3.2. DNA and RNA alkylation damage
Modification sites of DNA bases are the same for all alkylating agents and include all the
exocyclic nitrogens and oxygens, as well as ring nitrogens without hydrogen. Though all
DNA nucleobase oxygen or nitrogen atoms can be alkylated, the type and frequency of spe‐
cific damage varies depending on the type of alkylating agent, the structure of the substrate,
and the position of the damage site [13] (Table 1). Generally, alkylation damage at nitrogen
New Research Directions in DNA Repair126
molecules is less mutagenic than oxygen, though both types of alkylation damage are cyto‐
toxic and genotoxic [14].
Common alkylations generated by exogenous alkylating agents include O6-alkylguanine
and O4-alkylthymine adducts, as well as N7-alkylguanine, N3-alkyladenine, N1-alkylade‐
nine, and N3-alkylcytosine [13] (Figure 1). Moreover, the frequency of each adduct type de‐
pends on whether the DNA and RNA substrates are single- or double-stranded [13] (Table
1). For instance, nitrogen molecules involved in DNA base-pairing are less vulnerable to al‐
kylation damage than the same base nitrogens in a single-stranded region arising during
replication and transcription.
Table 1. % of Total DNA alkylation adduct formation in single- and double-strand DNA. Modifications following SN2
alkylating agent methylmethanesulfonate (MMS) or SN1 alkylating agent treatments methylnitrosourea (MNU) or
ethylnitrosourea (ENU). Sites where % alkylation is undetermined are indicated as (--) [13].
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4. Direct repair proteins
Numerous cellular mechanisms have evolved to deal with various types of DNA damage
and each DNA repair pathway is important to maintain genomic integrity. However, most
repair mechanisms require DNA synthesis and therefore an intrinsic risk of causing muta‐
tion in executing the repair. In contrast, direct repair proteins, MGMT and ALKBH family
proteins employ direct reversal mechanisms that result in complete restoration of DNA bas‐
es and are thus error-free mechanisms. Moreover, MGMT, ALKBH2, and ALKBH3 repair
endogenous and exogenous DNA and RNA alkylation damage at critical base-pairing sites,
facilitating proper replication of genetic information or transcription. This section will dis‐
cuss each of these direct DNA repair enzymes in detail.
Figure 4. Major mechanisms of alkylation adduct repair. Direct repair pathways are indicated in green. Base and nu‐
cleotide excision repair pathways are indicated in blue [2,14].
4.1. Mechanisms of alkylation repair
Multiple mechanisms are employed to rid the genome of alkyl adducts, thereby preventing
detrimental effects within the cell (Figure 4). Mismatch repair (MMR), base excision repair
(BER) and nucleotide excision repair (NER) and direct repair (DR) pathways all participate
in alkylation damage repair [15-24]. Specifically, BER and NER repair small alkylated base
damage including 7-methylguanine (7-meG) and 3-methyladenine (3-meA) DNA adducts
[25]. Although BER repairs the majority of small alkylated base damage (methyl and ethyl
adducts) the NER system can also remove small, as well as bulky adducts larger than ethy‐
lated bases [24, 26]. As an alternative to NER, incomplete BER repair intermediates can be
processed by homologous recombination (HR) [27]. However, BER, NER and HR repair
pathways generate strand breaks during repair of alkyl adducts and could introduce muta‐
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tions or rearrangements [28]. On the contrary, DR mechanisms, provided by methyltransfer‐
ase MGMT and ALKBH homologs, eliminate alkylation damage at DNA base-pairing sites,
including O6-methylguanine (O6-meG), 1-methyladenine (1-meA) and 3-methylcytosine (3-
meC) and do not require a nucleotide template, result in phosphodiester backbone break‐
age, nor do they require DNA synthesis.
4.2. Methyl Guanine Methyl Transferase (MGMT) proteins
In mammals, methylguanine DNA methyltransferase (MGMT or AGT), can repair two types
of DNA adducts: O6-methylguanine (O6-meG) and O4-methylthymine (O4-meT). O6-meG ad‐
ducts in DNA are extremely mutagenic [29, 30] and also block DNA polymerase extension,
which is generally associated with cytotoxicity [31, 32]. The primary mutations observed
when there is a failure to repair O6-meG adducts prior to replication are G:C฀A:T transi‐
tions, whereas a failure to repair O4-meT results primarily in T:A฀C:G transition mutations
[29]. In mammals, elimination of O6-meG by MGMT is preferred over O4-meT, but the re‐
spective efficiency of each type of reversion is species dependent [29, 33-37].
Removal of O6-meG and O4-meT modifications are achieved via a one-step methyltransfer‐
ase reaction, wherein MGMT accepts the alkyl adduct from the modified oxygen molecule,
onto an internal residue, directly restoring the DNA base and inactivating the protein [38]
(Figure 5). In addition to methyl groups, several other alkyl-adducts can also be transferred
from guanine to MGMT, including ethyl-, propyl- butyl-, benzyl- and 2-chloroethyl-. How‐
ever, the efficiency of the reaction is decreased for alkyl adducts greater than methylated
bases [39]. Once modified, the protein is targeted for elimination via the proteasome [40].
4.2.1. Protein structure/active site organization
Alkyltransferase proteins are found in eukaryotic and prokaryotic organisms and have been
identified in as many as 100 organisms [41]. Though sequences are not highly conserved be‐
tween human MGMT and Eubacterial, Archea, and Eukaryotic DNA methyltransferase en‐
zymes, structural domains and active site residues are almost identical [42-46].
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Figure 5. Methylguanine methyltransferase (MGMT) activity. (A) MGMT DNA repair substrates (B) MGMT repair reac‐
tion. Transfer of the methyl group (orange) from the damaged DNA base to the internal Cys145 (light green) is a sui‐
cide reaction, inactivating MGMT. [14]
In human MGMT, a conserved α/β roll structure, containing a three-stranded, anti-parallel
β-sheet, followed by two helices, make up the N-terminus (residues 1-85). The MGMT C-ter‐
minus (residues 86-207) contains a short, two-stranded, parallel β-sheet, four α-helices and a
310 helix [42, 47]. Found only in humans, a zinc ion stabilizes the interface between the N-
and C-termini, binding Cys5, Cys24, His29 and His85 in a tetrahedral conformation to
bridge three strands of the N-terminal β-sheet with the coil preceding the 310 helix in the C-
terminus [47].
The conserved active site cysteine motif (-PCHR-) is located in the C-terminus contained
within the DNA binding channel, and the helix-turn-helix (HTH) DNA binding motif. Resi‐
dues Try114-Ala121 form the first helix of the HTH motif and residues Ala127-Gly136 form
the second, “recognition” helix, which interacts with DNA. Linked by an Asn-hinge
(Asn137) that stabilizes the over-lapping turns by binding Val139, Ille143 and the Cys145
thiol, the -PHCR- active site is located near the “recognition” helix [42, 47, 48].
The active site of human MGMT is composed of at least ten residues that participate in sub‐
strate binding, enzyme structure and alkyl transfer. Residues Val155-Gly160 and Met134
generate a hydrophobic cleft in the active site loop, while residues Tyr114, His146, Val148,
Ser159, and Glu172 participate in active site coordination and alkyl group transfer to residue
Cys145. Not unexpectedly, mutation of residue Cys145 results in elimination of alkyl group
transfer, however substrate binding is unaffected [49] (Figure 6).
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Figure 6. Structure of human MGMT (PDBid1QNT). The N-termianl p-sheet and C-terminal 310 helix of the α/β roll
structure, conserved in AGT proteins are indicated. In humans, a zinc ion stabilizes interaction of MGMT N-and C-ter‐
mini [46].
4.2.2. Substrate recognition/repair mechanism
In repair, MGMT is unique in that one molecule is responsible for the removal of one O6-
meG or O4-meT adduct. Unlike most enzymes with the capacity to catalyze multiple reac‐
tions, MGMT catalyzed reactions are stoichiometric and capable of only a single repair
reaction [50]. As a result, removal of O6-meG and O4-meT alkyl adducts is dependent on
both MGMT and the substrate concentrations (second-order reaction).
The recognition of guanine and thymine base methylation is accomplished by a highly con‐
served amino acid structure. The hydrophobic cleft of the active site loop and -PCHR- motif
within the binding channel allow MGMT to bind to the minor-groove of DNA using resi‐
dues Ala126, Ala127, Ala129, Gly131, and Gly132, of the HTH “recognition” helix [51, 52],
which is followed by necessary conformational changes to orient the damaged base within
the active site.
Identified based on bacterial Ada homology and human MGMT structures, following sub‐
strate recognition, the target base is repaired using a base flipping mechanism [53-58]. In the
MGMT repair reaction, the damaged base undergoes a residue Tyr114-mediated, sterically
enforced 3’ phosphate rotation into the active-site pocket. The hydrophobic cleft formed by
the active site loop easily accepts the extra-helical base, causing the DNA minor groove to
widen [51]. The arginine finger residue, Arg128, intercalates between the DNA bases and in‐
teracts with the unpaired cytosine, via a charged hydrogen bond [55], maintaining an appro‐
priate DNA duplex conformation (Figure 6).
Once bound within the MGMT active site, numerous residues participate in the methyl‐
transferase reaction. A hydrogen bond network, conserved in AGTs, is formed between
Glu172, His146, water and Cys145. His146 acts as a water-mediated base that deprotonates
Cys145, converting Cys145 to a cystine thiolate anion and generating an imidazolium ion
Direct Repair in Mammalian Cells
http://dx.doi.org/10.5772/54449
131
that is stabilized by Glu172 [35, 59]. Residues, Val148 and Cys145 carbonyls accept guanine
exocyclic amine hydrogen bonds and nitrogen atoms of residues Tyr114 and Ser159 donate
protons to N3 and O6 of O6-meG, respectively. The deprotonated Tyr114 residue abstracts a
proton from Lys165, simultaneously transferring the alkyl group from the O6 position of
guanine to the thiolate anion of the Cys145 residue [35]. Transfer of the alkyl group gener‐
ates a thioether, S-alkylcysteine, and results in complete restoration of the guanine base, as
well as irreversible inactivation of the methyltransferase enzyme (Figure 5). While many
DNA repair proteins have a specific requirement for double-stranded DNA, MGMT can also
bind to single-stranded DNA [60].
4.2.3. Gene expression/protein regulation
Removal of O6-meG modifications by MGMT has a major role in cell cycle checkpoint con‐
trol, proliferation, and differentiation [61]. As a result, MGMT is a house-keeping gene that
is expressed in all tissues; though expression varies depending on cell type [62]. MGMT ex‐
pression in an individual cell or tissue type is dependent on a variety of factors, including
numerous types of stimuli and promoter regulator elements. However, the relationship be‐
tween factors that mediate MGMT expression and the regulation of its function is not well-
understood. The lack of understanding regarding the consequences of MGMT regulation is
illustrated by the fact that MGMT expression is silenced in some cancers, but expression is
up-regulated in others [62, 63].
MGMT  is  a single gene on chromosome 10q26,  spanning approximately 300kb [64].  The
gene  has  five  exons,  but  the  first  is  non-coding  [65,  66].  The  promoter  of  MGMT  is  a
non-TATA-box promoter that  contains a GC-rich CpG island of 780 bp that includes 97
CpG dinucleotides [67].  CpG islands are commonly associated with promoter regions of
constitutively  expressed  genes,  from  which  transcription  is  initiated  from  a  single  pro‐
moter  site  [68-70].  Additionally,  the promoter  contains six  transcription consensus bind‐
ing sites (SP1, AP1, and AP2), three upstream and three downstream of the transcription
start site, a glucocorticoid-responsive element, and a 3’ enhancer element [62, 67, 69, 71].
Though unmethylated in normal cells,  promoter CpG island methylation-induced silenc‐
ing of MGMT is found in various cancer types and MGMT-deficient cell lines and is one
mechanism that regulates MGMT expression [72-76]. However, whether MGMT promoter
methylation disables transcription factor binding or contributes to chromatin reorganiza‐
tion remains uncertain [71, 75].
In addition to numerous transcription factor binding sites that surround the MGMT promot‐
er transcription start site, the MGMT promoter CpG islands exhibit a chromatin structure
that mediates interaction with transcription factors. The MGMT gene is organized around
five or more nucleosomes in a manner that positions 300 bp region of the promoter se‐
quence, which contains known MGMT transcription factor binding sites, so that it does not
lie within the nucleosomes, and therefore does not maintain a higher-order chromatin struc‐
ture [62, 72, 77]. Such nucleosomal positioning facilitates an “open” stretch of DNA that ena‐
bles constitutive interaction of transcription factors with the promoter.
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Methylation of the CpG island surrounding the transcription factor binding sites contributes
to lack of transcription factor binding, but could also effect nucleosomal positioning of the
MGMT promoter [62, 71], suggested by histone H3 Lys9 (H3K9) di-methylation, exhibited in
relationship to MGMT silencing [78, 79]. Further, deacetylation of histones H3 and H4 could
also be associated nucleosome organization that is more condensed, resulting in transcrip‐
tion inactivation. Therefore, the chromatin structure of the MGMT promoter, as well as CpG
island methylation, mediate transcription factor access to the promoter and are important
for MGMT expression.
4.2.4. Protein localization and cell type dependence
Immunofluorescence studies indicate MGMT nuclear localization at discrete nuclear regions
[80]. Although a nuclear localization signal (NLS) for MGMT has not been identified, the
small size of MGMT, 23 kDa, may not require an active translocation signal to traverse nu‐
clear pores [53]. However, a –PKAAR- sequence within the DNA binding domain of MGMT
is necessary for DNA interactions to facilitate nuclear retention [81]. The highest MGMT ex‐
pression levels are found in the liver, where high levels of endogenous nitrosating agents
are present, but MGMT is also expressed at high levels in the lung, kidney and colon.
MGMT expression is heterogeneous in the brain and the lowest levels are observed in the
pancreas, hematopoietic cells, lymphoid tissues [62, 67, 82-86].
4.2.5. Post-translational modification
Once MGMT has transferred a methyl group to its  Cys145 residue,  no further reactions
are catalyzed, so the protein must be eliminated. The degradation of MGMT is an ubiq‐
uitination-dependent process that has been evaluated using inactivation of the protein by
O6-BzG, BCNU, or NO-generating agents at position Cys145 [40, 87, 88].  Conformational
changes in the protein structure after  alkyl  group transfer  target  MGMT for  ubiquitina‐
tion and proteasomal degradation [40, 89]. Two sites within MGMT, Lys125 and Lys178,
have been identified as ubiquitination targets in B lymphocyte (NCI-H929) or 293T, and
myeloid (MV4-11) cells, respectively. Additionally, examination of potential MGMT mod‐
ification sites using predictive software also identifies Lys104 as an ubiquitination target.
Furthermore,  predictions  also  indicate  post-translational  modification  sites  for  methyla‐
tion (Arg128, Arg135), acetylation (Lys8, 125, 178, 193), and sumoylation (Lys75, 205, 18,
107), as well as numerous phosphorylation sites (Ser36, 56, 130, 182, 202, 206, 208; Thr37;
Tyr91,  115)  [90-93],  which  all  merit  further  consideration.  Notably,  phosphorylation  of
residues  Thr10  and  Thr11  was  also  noted  in  HeLa  cells  [92],  and  phosphorylation  of
Ser201 is  observed in B lymphocyte cells  (DG75 and GM00130),  KGI myeloid cells,  and
HeLa cervical  cancer  cells.  Importantly,  crystallographic  data  suggests  that  modification
of Ser201 could disrupt interaction with DNA [48, 51, 55].
4.3. Alkbh Fe(II)/α-ketoglutarate-dependent dioxygenases
In mammals, repair of cytosine and adenine base methylation at base-pairing positions is
specifically associated with the AlkB family dioxygenase proteins [92, 94-96]. Discovered
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first in Escherichia coli (E. coli) in 1983 [96] alkylation protein B (AlkB) belongs to a super-
family of Fe(II)/α-ketoglutarate-dependent dioxygenases (FeKGDs), with roles in histone de‐
methylation [97-99], proline hydroxylation [95] and in the case of AlkB, the ability to directly
remove alkyl adducts generated in DNA residues as a result of exposure to SN2 alkylating
agents [94, 100]. Originally predicted to act on 1-methyladenine (1-meA) and 3-methylcyto‐
sine (3-meC), bacterial AlkB has been shown to repair a variety of DNA and RNA adducts,
including 1-meA, 3-meC, 1-meG, 3-meT, 1-etA, as well as aromatic ethyl, 3-etC, and etheno
adducts, 1,N6-ethenoadenine (εA) and 3,N4-ethenocytosine (εC) [94, 100-108] (Figure 7).
Using bioinformatics, nine human ALKBH family enzymes, ALKBH1-8 and FTO, were
identified, of which only four have been reported to have DNA repair activity, ALKBH1 –
ALKBH3 and FTO [109, 110]. Though all of the ALKBH homologs contain conserved cata‐
lytic domain residues, none entirely encompass the enzymatic activity of AlkB [15, 103, 104,
111-114]. Removal of alkyl adducts from DNA is only accomplished by three ALKBH pro‐
teins, ALKBH1-3, known to remove 1-meA and 3-meC adducts. However, ALKBH1 is re‐
portedly a mitochondrial protein [115], therefore in the nucleus ALKBH2 and ALKBH3
proteins are employed to remove specific adducts in single- or double-stranded DNA or in
RNA [104]. Lesions that are repaired by ALKBH proteins generally interfere with base-pair‐
ing and block replication and transcription, triggering cell cycle checkpoints and apoptosis
[92, 95, 96, 110, 115]. In E. coli AlkB mutants, as well as in Alkbh2- or Alkbh3-deficient
mouse embryonic fibroblasts, cells exhibit increased sensitivity to alkylating agents, particu‐
larly the SN2 type, and increased mutant frequency [101, 116-119].
Figure 7. ALKBH protein substrates. (A) DNA methyl adducts repaired by ALKBH proteins. (B) DNA etheno adducts
repaired by ALKHB proteins.
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4.3.1. Protein structure/active site organization
Similar to MGMT, the sequences of human ALKBH proteins do not contain a high percent‐
age of sequence homology in regions other than active sites and conserved domains, but do
have conserved secondary structures [109, 110, 114, 120-122]. In AlkB family proteins, the
catalytic core is composed of three major components, the double-stranded β-helix (DSBH),
the nucleotide recognition lid (NRL) and the N-terminal extension (NTE) (Figure 8). The
DSBH is comprised of eight β-strands in the C-terminal portion that form two β-sheets to
create a central core jelly-roll fold. Within the major and minor β-sheets of the DSBH lie con‐
served catalytic residues RxxxxxR and HxDxnH, respectively [120, 121, 123]. The HxD dyad
is near the amino terminal end and is located in a flexible loop that follows the first strand,
stacking with the minor β-sheet. The carboxy-terminal histidine of the conserved HxDxnH
residues is associated with the beginning of the sixth strand and together these residues co‐
ordinate iron (His171, Asp173 and His236—Alkbh2; His191, Asp193 and His258—Alkbh3)
[114, 120, 121, 123, 124]. The histidine and aspartic acid residues (Asp248 and Asp254—
ALKBH2; Asp269 and Asp275—ALKBH3), conserved in the DSBH minor β-sheet, coordi‐
nate Fe(II), α-ketoglutarate and the DNA or RNA repair substrate within the catalytic core.
A conserved Arg residue in the C-terminal β-strand (Arg254—ALKBH2 and Arg275—
ALKBH3) sets AlkB family proteins apart from other α-ketoglutarate-dependent dioxyge‐
nases within the Fe(II)/α-ketoglutarate dioxygenase superfamily, forming the base of the
















Figure 8. Structure of human AlkB homolog DNA repair proteins. Two looped structures (flip1 and flip2) generated by
anti-parallel β-sheets create the nucleotide recognition lid (NRL) and are involved in DNA base flipping. (A) Structure
of ALKBH2 (PDBid3BTX). ALKBH2 double-strand DNA substrate specificity is facilitated by residues in loops L1 and L2.
(B) Structure of ALKBH3 (PDBid2IUW). β -sheets 4 and 5 form the β-hairpin motif in ALKBH3. Part of loop 1, involved in
ALKBH substrate specificity, was omitted due to electron density problems. [121]
The N-terminal extension (NTE) and Nucleotide Recognition Lid (NRL) are formed by the
β-hairpin motifs that extend from the DSBH jelly-roll, forming a substrate binding groove
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that covers the active site until bound. Ninety residues are contained within two looped
structures, forming “flips” that lie between a single β-sheet and two α-helices in the N-ter‐
minal portion of the catalytic core [120, 121]. Secondary structures are of similar size, but
possess different characteristics important for substrate specificity and DNA activity. In
ALKBH2, the first flip is 20 residues that make up a β-hairpin and short α-helix, creating a
hydrophobic binding groove. In contrast, the first flip in ALKBH3 is a β-hairpin made up of
17 residues that form a hydrophilic, positively charged binding groove, more suitable for
single-stranded DNA or RNA substrates [15, 120]. The characteristics of the second flip are
also unique. Flip two of ALKBH2 spans 24 residues that is made up of three β-sheets, with
numerous sites for DNA substrate interaction. The orientation of the three β-sheets, which
fold back towards the C-terminal end of the first α-helix, is also unique only to ALKBH2
[114, 121]. However, flip 2 of ALKBH3 is only 12 residues and contains a single β-sheet
[114]. The N-terminal regions of each ALKBH homolog are more variable and hypothesized
to play roles in sub-cellular sorting and protein-protein interactions [114, 115] (Figure 8).
In addition to the conserved catalytic dioxygenase residues, some human ALKBH proteins
also contain additional catalytic residues and domains [104, 109, 110, 113, 125] (Figure 9).
Structural analysis of bacterial AlkB and human ALKBH homologs provides insight into
substrate preferences and repair capabilities. For instance, ALKBH2 contains three unique
motifs that facilitate enhanced activity on double-stranded DNA [121]. A long, flexible β-
sheet hairpin loop that contains DNA binding residues Arg198, Gly204 and Lys205, a short
loop that contains the RKK motif (Arg241-Lys243) and an aromatic finger residue (Phe102)
are used to make contacts with both DNA strands, rotate and take the place of the damaged
base in duplex DNA molecules. On the other hand, the number and organization of the cata‐
lytic domains in ALKBH3 result in differential manipulation of the DNA backbone, explain‐
ing the preference for single-strand substrates. Lack of an aromatic finger residue and RKK
motif in ALKBH3, the damaged base is squeezed on either side, forcing it to rotate, and the
immediate 5’ and 3’ bases to stack against one another. However, structural analysis of
ALKBH3 has identified residue Arg122, specifically the arginine side chain length, as impor‐
tant for double-stranded DNA substrate activity, possibly mimicking the base-flipping and
stacking activities of ALKBH2 residue Phe102 [114, 121].
Unfortunately, extensive biochemical analysis or structural studies have not been conducted
on ALKBH homologs 4-8. However, it is apparent that differences in the number and organ‐
ization of catalytic residues, as well as secondary structures play a large role in the diversity
of ALKBH family protein substrate specificities and enzymatic activities [113]. For instance,
although single- or double-strand DNA repair activity has not been established for
ALKBH8, the presence of RNA binding and methyltransferase domains in ALKBH8 (Figure
9) suggested that this homolog plays a role in maintenance of methylation patterns. Investi‐
gation of such activities led to the identification of ALKBH8 tRNA methyltransferase activi‐
ty, necessary in the biogenesis of wobble uridine modifications utilized in translational
decoding [126, 127].
New Research Directions in DNA Repair136
Figure 9. AlkB family protein domain alignment. Conserved amino acid sequences and domain function are indicated.
The total number of amino acids is indicated to the right of each homolog. [110,113,125]
4.3.2. Substrate recognition/repair mechanism
Initially, it was predicted that AlkB family proteins directly repaired alkylation adducts by
hydroxylating methyl groups and removing the resultant hydroxymethyl groups via an oxi‐
dative reaction that directly restores the undamaged base [94, 109, 112, 124, 128, 129]. How‐
ever, specific investigation of the AlkB family dealkylation mechanism [130] determined
that the direct repair reaction mediated by AlkB family proteins involves several intermedi‐
ate steps that had not yet been identified. Regardless, dealkylation catalyzed by AlkB and its
human homologs occurs via transformation of α-ketoglutarate into succinate, formaldehyde
release, and restoration of the undamaged base [94, 100, 111, 130, 131] (Figure 10).
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Figure 10. ALKBH protein repair reactions. (A) ALKBH methyl adduct repair reaction. (B) ALKBH ethyl adduct repair
reaction. (C) ALKBH etheno adduct repair reaction. Repair of ethyl and etheno adducts requires the same co-factors,
but displaces acetaldehyde or water and glyoxal as byproducts of the repair reaction, respectively, instead of formal‐
dehyde [100,102,103]
First, Fe(II) and three water molecules must be coordinated within the conserved catalytic core,
stimulating α-ketoglutarate (KG) binding in the catalytic pocket. Binding of α-KG into the cata‐
lytic pocket chelates Fe(II) by displacing two water molecules to create the Fe(II)/α-KG active-
site  complex.  Ligation of  dioxygen to the Fe(II)  molecule displaces  the remaining water
molecule, generating a ferric-superoxido species that undergoes self-redox and nucleophilic
attack on the α-keto group. This nucleophilic attack is necessary to decarboxylate α-KG, releas‐
ing succinate and generating a ferryl-oxo intermediate. Reorientation of this intermediate facil‐
itates  removal  of  a  hydrogen  atom  from  the  methyl  adduct.  Finally,  radical  rebound
hydroxylation of the methylene group results in decomposition of the hydroxymethyl nucleo‐
base, yielding formaldehyde and the repaired nucleobase. Though two co-factors were noted
initially, α-ketoglutarate and Fe(II), ascorbate also plays a role, helping to convert the Fe(III) to
Fe(II), thereby regenerating the original oxidative state of iron in the Alkbh proteins that per‐
mits enzymatic cycling [94, 111, 112, 122, 124, 130].
The major methylated bases repaired by ALKBH proteins are 1-methyladenine (1-meA) and
3-methylcytosine (3-meC), however homologs have also been reported to repair ethylated,
and some etheno and exocyclic bases [102-105, 107, 131, 132]. Similar mechanisms are pro‐
posed for repair of ethano and exocyclic etheno (ε) adducts, though the final steps of these
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reactions result in release of acetylaldehyde and glycol, respectively [130] (Figure 10). How‐
ever, additional biochemical studies are needed to confirm these mechanisms in similar de‐
tail to removal of methyl adducts from DNA.
4.3.3. Gene expression/protein regulation
Human AlkB DNA repair homologs, ALKBH2 and ALKBH3 are single genes on chromo‐
somes 12q24 and 11p11, respectively. Expression of human AlkB homologs has been report‐
ed in a variety of normal tissue samples, including ALKBH homologs 4-8, despite the lack of
DNA repair activity in the literature [133]. Expression of ALKBH family proteins varies de‐
pending on cell types. Protein expression levels in the various tissue types vary depending
on the homolog evaluated. Little is known of ALKBH protein regulation mechanisms and is
an area in need of further study.
4.3.4. Protein localization and cell type dependence
Differences amongst AlkB homolog proteins in their biological roles are partially ascribed to
their sub-cellular localizations. ALKBH2 and ALKBH3 homolog proteins are expressed at the
highest levels in the testis and ovary, however detectable expression of all AlkB homolog pro‐
teins is exhibited in the spleen, pancreas, lung, kidney, prostate and brain [133]. Although
ALKBH1 activity is confined to mitochondria [115], immunofluorescence imaging indicates
that the protein is cytoplasmic and nuclear [133]. Similarly, AlkB homolog proteins ALKBH3, 4,
6, and 7 are also present in the nucleus and cytoplasm [133], though ALKBH3 is the only homo‐
log reported to possess repair activity [1, 104, 111]. Localization of ALKBH3 in both the nucleus
and cytoplasm are consistent with identified interactions with helicase enzymes to facilitate
DNA repair [134] and roles in mRNA repair [131]. ALKBH2 is present only in the nucleus and
exhibits diffuse as well as localized, punctate staining, supporting pre-established co-localiza‐
tion with PCNA at replication foci during S phase [111, 131, 133], suggesting a role in replica‐
tion- and transcription-related repair, as well as genome maintenance. On the contrary, AlkB
homolog proteins ALKBH5 and 8 are present only in the cytoplasm [133], which supports
known ALKBH8 tRNA methyltransferase activity [126, 127].
4.3.5. Post-translational modification
Unlike MGMT, ALKBH proteins are not suicide enzymes and a single protein can cata‐
lyze multiple direct repair reactions, requiring only ascorbate to regenerate the Fe(II) ac‐
tive  site  center  [135].  Therefore,  immediate  degradation  of  ALKBH  proteins  following
repair is not required, as it is for MGMT. Other possible post-translational modifications
in  ALKBH2  and  ALKBH3  include  candidate  sites  for  phosphorylation  and  acetylation.
Mass-spectrometric  analysis  of  a  curated  database  of  cell  lines  revealed  that  both
ALKBH2 and ALKBH3 proteins  undergo post-translational  modification of  specific  resi‐
dues present in various cancer types [92].
Post-translational modifications curated for ALKBH2 include acetylation of residue Lys34
and Lys104 in various colorectal cancer cell types (HCT116, HT29, XY3-92-T and XY3-68-T),
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as well as phosphorylation of residue Thr252 in esophageal cancer cell line XY2-E111N [92].
Though the exact effects of these modifications are unknown, it is important to state that
Lys34 is within the variable region of the N-terminus that is thought to provide protein spe‐
cificity. Similarly, Lys104 is between two residues that make contact with the complimenta‐
ry DNA strand during double-strand DNA repair and Thr230 is a residue in the most C-
terminal α-helix of the active site [92]. Examination of potential ALKBH2 modification sites
using predictive software shows possible post-translational modification sites for methyla‐
tion (Arg128, 135), sumoylation (Lys75, 205), and ubiquitination (Lys104), along with other
possible phosphorylation sites (Ser36, 56, 130, 182, 202, 206, 208; Thr37; Tyr91, 115) [90-93].
All of those possible post-translational modifications merit further consideration.
Post-translational modifications were also present in ALKBH3, corresponding to various
disease states. Phosphorylation of Thr126 and Tyr127 residues in the β-hairpin of the NRL,
as well as residue Try229 in the ALKBH3 active site, was present in acute myelogenous,
chronic myelogenous and/or T-cell leukemia [92]. Additionally, phosphorylation of Tyr127
was exhibited in lung and non-small cell lung cancer cell lines. Phosphorylation of residue
Tyr143, which precedes the first residue of the second β-hairpin in the NRL, was also noted
in the gastric carcinoma cell line MKN-45, as well as phosphorylation of residues T212 and
T214, within the ALKBH3 active site, was found in liver cancer tissue samples [92]. Exami‐
nation of potential ALKBH3 modification sites using predictive software shows possible
post-translational modification sites for acetylation (Lys43, 116, 219, 220), and sumoylation
(Lys57, 236), along with other possible phosphorylation sites (Ser32, 50, 187, 192, 208, 265;
Thr29, 41; Tyr78, 127, 229) [90-93]. All of those possible post-translational modifications mer‐
it further consideration.
5. Biological significance of direct repair in mammalian cells
Normal cells depend on direct repair to eliminate damage that is possibly cytotoxic or muta‐
genic. Our knowledge of the biological significance of direct repair proteins in mammalian
cells is based on the evaluation of effects on cell cytotoxicity, replication, transcription and
subsequent mutagenic consequences observed in the absence of each protein of interest. Re‐
cent investigations performed in model system organisms, most prominently in mice, to as‐
sess the impact of the absence of Mgmt or Alkbh family proteins will be highlighted in this
section. These studies also provide insight into the function and importance of direct repair
proteins in humans.
5.1. Knock-out animal models
It is important to remember that a number of DNA repair systems are implicated in the
elimination of DNA lesions formed by exposure to alkylating agents. Therefore, dysfunction
of repair systems can lead to pathologies that include cancer development. However, with‐
out use of a model organism to assay the effects, the consequences to the organism as a
whole cannot be assessed. Knock-out animal models are a valuable tool for understanding
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the overall physiological effects of genes on an organism, and provide insight into disease
research and therapeutic development.
Murine Mgmt models have been studied by multiple groups to evaluate sensitivity to alky‐
lating agents commonly used in chemotherapeutics [5, 6, 82, 86, 136-139]. Though Mgmt re‐
pairs DNA damage that is known to be mutagenic, Mgmt-deficient mice surprisingly lack
any overt phenotype. However, these mice are significantly more sensitive to treatment with
N-methyl-N-nitrosourea (MNU), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(4-amino-2-
methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)3-nitrosourea (ACNU), streptozotocin, temo‐
zolomide, and dacarbazine alkylating agents [5, 136, 137, 139-142]. Mgmt knock-out mice
treated with various chemotherapeutic agents also show ablation of hematopoietic tissues at
the stem cell level [38, 141, 143] and are prone to development of thymic lymphomas
[144]and lung adenomas [82, 138, 144, 145]. Similarly, mouse embryonic stem (ES), embry‐
onic fibroblasts (MEFs) and bone marrow cells deficient in Mgmt also exhibit a significant
increase in sensitivity (~10-fold) to MNU and BCNU [83, 141, 146]. However, mice heterozy‐
gous for Mgmt do not display a significant reduction in survival following treatment with
nitrosoureas or increased tumorigenesis, compared to their wild-type counterparts.
Although in vitro DNA repair activity has been established for ALKBH1, studies conducted
in murine models lacking Alkbh1 suggest roles involved in transcription. Mice deficient in
Alkbh1 exhibit apoptosis in adult testis, sex-ratio distortion and unilaterial eye defects, as
well as impaired differentiation of specific trophoblast lineages in the developing placenta
[147, 148]. Though the specific activity and function of ALKBH1 remains to be determined,
ALKBH1 biological roles seem linked to spermatogenesis and embryonic development.
On the other hand, Alkbh2- and/or Alkbh3-deficient murine models do not manifest any ob‐
vious phenotype or histopathological changes [116, 119, 132]. However, over time mice lack‐
ing Alkbh2 accumulate significant levels of 1-meA, confirming a role in removing
endogenous DNA alkyl adducts. In a recent study, Alkbh2,Alkbh3,Aag knock-out mice (Aag
also known as Mpg, a DNA glycosylase in the BER pathway) were viable, but underwent
rapid death when exposed to a chemically-induced colitis treatment [119]. Similarly, pri‐
mary mouse embryonic fibroblasts (MEFs) derived from mice lacking functional Alkbh2 ex‐
hibited significantly increased cytotoxicity and mutagenesis following exposure to the SN2
alkylating agent methyl methanesulfonate (MMS) [116, 118, 119]. Survival of Alkbh3-defi‐
cient MEFs exposed to MMS was reduced by ~50% compared to wild type MEF sensitivity,
though mutant frequency did not significantly increase [116].
5.2. Replication and transcription defects
Though not all lesions generated by exposure to alkylating agents cause defects in repli‐
cation and transcription, DNA and RNA adducts that are specifically removed via a di‐
rect  repair  mechanism  interfere  with  replication  and  transcription  machinery.  The
presence  of  O6-meG  in  DNA  impedes  polymerization  by  DNA  and  RNA  polymerases
[31,  32,  149,  150].  Polymerase beta (β),  involved in base excision repair  (BER) of  alkyla‐
tion  adducts,  is  completely  blocked  by  O6-meG  adducts  [150].  Polymerase  delta  (δ)  is
able to replicate past, but insertion of the correct base opposite O6-methylguanine is very
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inefficient.  However,  these  adducts  can  be  bypassed  using  polymerase  eta  (η)  [149],  a
member of the Y-family DNA translesion synthesis (TLS) polymerases, but TLS polymer‐
ases  are  notorious  for  being  error-prone.  Interestingly,  when  replicating  past  O6-meG
DNA adducts,  TLS polymerase,  Polη is  twice as efficient  at  inserting cytosines opposite
O6-meG as replicative polymerase, Pol δ [32].
1-meA and 3-meC lesions that are repaired by Alkbh2 and Alkbh3 are at DNA base-pairing
positions and hinder proper base insertion [101]. During replication, this can lead to arrest
of nucleotide synthesis, resulting in replication fork collapse [151]. Similarly, 1-meA and 3-
meC adducts can also cause stalling of transcription. Correspondingly, Alkbh2 co-localizes
with replication foci during S-phase [111, 131, 133] and Alkbh3 has a role in removal of alkyl
adducts from mRNA [1, 15, 108, 115, 131, 152]. However, a TLS polymerase that is linked to
1-meA and/or 3-meC DNA adduct bypass has not been identified.
5.3. Cell cytotoxicity
Treatment with alkylating agents introduces a variety of adducts into DNA and RNA (Fig‐
ure 2, Table 1). In the absence of direct repair proteins, those lesions can lead to cell death or
damage tolerance, which allows for cell survival, but can introduce mutations into the ge‐
nome that could have detrimental effects [101, 116, 142, 153]. As exhibited in Mgmt- and
Alkbh-deficient murine models, lack of direct repair proteins correlates with a significant in‐
crease in cell death following treatment with SN1 or SN2 alkylating agents, respectively [116,
118, 140, 141].
5.4. Mutagenesis
When a modified nucleoside can form at least two hydrogen bonds, transcription and repli‐
cation templates and translation of messengers are active [13]. O6-meG, 1-meA, and 3-meC
are all involved in DNA base-pairing. Modification at O6-meG and 3-meC still allow for for‐
mation of two hydrogen bonds, while 1-meA results in only a single hydrogen bond be‐
tween paired bases [13]. However, the exocyclic amino group of 1-meA can rotate so that
both amino group hydrogen molecules can generate the necessary base-pairing bonds,
though a slight distortion of the double-strand DNA helix does occur [13]. The addition of a
methyl group to O6-G, N1-A, or N3-C interferes with normal replication, and could recruit
DNA translesion synthesis (TLS) polymerases to bypass the DNA adducts. The size and or‐
ganization of the Y-family TLS polymerase active sites is variable and allows for accommo‐
dation of numerous adducts. However, not only are TLS polymerases inherently error-
prone [154, 155], the number and type of hydrogen bonds that can be made with the
modified bases has been altered. Those factors can produce insertion of an erroneous base
during bypass that accompanies replication or transcription.
O6-meG mutagenicity has been established in bacterial and mammalian systems [29, 30]. O6-
meG is mutagenic and primarily gives rise to G:C→A:T mutations. A mis-insertion of thy‐
mine is thought to occur due to mis-identification of O6-meG as adenine, as hydrogen
bonding can occur with the N1 and exocyclic amino group of O6-meG [13].
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Unfortunately, studies evaluating the mutagenicity of a site-specific 1-meA, 3-meC, 1-meG,
or 3-meT adducts have not been conducted in mammalian systems, but studies in E. coli,
show that 1-meA adducts are only slightly mutagenic, whereas 3-meC, 1-meG, and 3-meT
adducts are much more mutagenic [101]. Work evaluating the anti-mutagenic role of Alkbh2
and Alkbh3 in a murine model showed increased mutant frequency, specifically for mouse
embryonic fibroblast (MEF) cells deficient in either Alkbh2 or Alkbh3 [116]. Those Alkbh-
deficient cells exhibited increased amounts of C:G→A:T C:G→T:A mutations, respectively.
Additionally, when treated with MMS, Alkbh2-deficient MEFs displayed an increased fre‐
quency of C:G→T:A and T:A→A:T mutations. Similarly, Alkbh3-deficient MEFs also exhibit‐
ed an increased frequency of T:A→A:T mutations, as well as an increased frequency of
A:T→G:C mutations, in response to MMS treatment. Like O6-meG, misidentification of the
modified DNA bases due to the presence of two sites for hydrogen bond formation could
arise if 1-meG or 3-meC is recognized as thymine and an adenine is paired with the two re‐
maining hydrogen bond acceptors. Furthermore, T:A→A:T mutations could arise if 3-meT
becomes recognized as adenine and a thymine is paired via hydrogen bonds between thy‐
mine O4 and O2 and adenine N-3 exocyclic amino group nitrogen. It is likely that 1-meA is
rarely mutagenic in E. coli, deficient in AlkB, because 1-meA can utilize the C6 exocyclic
amine and N7 as an alternative binding site providing two sites for hydrogen bond forma‐
tion with thymine N-7 and O4 molecules, using Hoogsteen base-pairing [156].
6. Medical significance of direct repair proteins in humans
Genetic and epigenetic controls that regulate MGMT, ALKBH2, and ALKBH3 gene expres‐
sion and influence how these proteins directly repair DNA are critical factors that can lead
to a better understanding of cancer development. In addition, comprehension of factors that
cause variations in the direct DNA repair activities of cancer cells will provide important
progress toward formulating cancer therapeutics that target MGMT or ALKBH proteins.
Understanding the impact of direct DNA repair proteins will eventually result in treatments
that can be tailored to achieve better therapeutic results or to predict treatment and/or dis‐
ease outcomes.
6.1. Epigenetic and transcriptional regulation
Epigenetic modifications are stable alterations of DNA that are heritable in the short term,
but do not involve mutations of the DNA itself, and are mediated by DNA methylation and
histone modifications. The stable alterations that are involved in epigenetics have a major
role in exerting control on gene expression. Endogenous cell signaling as well as external in‐
fluences, including diet and other life style choices, can alter gene expression mediated by
changes in epigenetic modifications [157, 158]. Methylation of cytosines at transcription fac‐
tor recognition sites can interfere with binding and/or function and repress transcription of
that gene [159, 160]. Alternatively, protein recruitment that binds methyl CpG islands can
block transcription machinery or alter chromatin structure [161, 162]. Transcriptional silenc‐
ing also is connected to histone deacetylation [163, 164]. Methyl CpG binding domain
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(MBD) family proteins direct histone deacetylases to remove acetyl groups from lysines in
the amino terminal histone tails, stabilizing DNA-histone interactions, and condensing chro‐
matin so that transcription factor binding sites are inaccessible.
Though unmethylated in normal cells, transcriptional silencing of MGMT, associated with
promoter CpG island methylation has been reported in a variety of cancer cell types and
MGMT-deficient cell lines [82, 138]. Additionally, in a glioma mouse model a subpopulation
of glioma cells with stem cell properties were identified [165] that are capable of re-estab‐
lishing tumor growth following temozolomide treatment. Although Mgmt promoter CpG
methylation or protein levels were not determined in that study, when MGMT transcript
levels were evaluated in glioma patients [166], those with MGMT CpG promoter methyla‐
tion had increased response to temozolomide, but also maintained a subset of glioma cells
with stem cell-like character and MGMT promoter methylation. Interestingly, mRNA levels
of DNMT1 and DNMT3b methyltransferases are increased in a number of human glioma pa‐
tients, but there does not appear to be a link to MGMT expression levels [167]. Moreover,
MGMT promoter CpG methylation levels and DNA methyltransferase levels alone do not
account for patient response to alkylating agent therapy. However, whether MGMT promot‐
er methylation disables transcription factor binding or contributes to chromatin reorganiza‐
tion remains uncertain [71, 72, 74]. Therefore, regulation of MGMT expression is still unclear
and merits intense scrutiny.
The inability to establish direct connections among MGMT expression, CpG methylation,
and response to alkylating agent therapy indicates that other mechanisms contribute in reg‐
ulating MGMT levels. Studies evaluating MGMT expression and microRNAs in patient sam‐
ples have established a modest inverse correlation between the levels of MGMT transcript
and miR-181d [168]. Moreover, expression of mi-181d in A1207 glioblastoma cells, results in
abnormal sensitivity to temozolomide. However, expression of MGMT cDNA, restores the
survival to levels close to that of the A1207 parental line. These results suggest that identifi‐
cation of other miRNAs involved in regulating MGMT expression will help elucidate the
mechanisms that control the gene transcript levels.
In addition to control at the DNA and transcript levels, histone modifications can also con‐
trol the epigenetic state and direct expression. Acetylated histone H3 and H4 levels also in‐
crease in cell lines expressing MGMT, compared to cell lines deficient in MGMT [169],
which would facilitate nucleosomal positioning that enables transcription factor interac‐
tions. Further, binding of MBD proteins in the MGMT promoter of was greater in MGMT-
silenced cells, implicating MBD proteins in recruitment of histone deactylases that remove
lysine acetylation from the amino-terminal tails of histones H3 and H4, resulting in more
condensed chromatin and transcription inactivation [73, 79, 170]. Therefore, epigenetic
and/or enzymatic CpG island methylation at the MGMT promoter influences transcription
factor access, as well as chromatin structure that are important for MGMT expression.
ALKBH2 and ALKBH3 both have CpG islands in their promoters, but epigenetic regulation
and/or gene silencing has not been reported for either homolog. However, mutations that
alter protein expression have been observed [171], but it is likely that methylation of CpG
islands near any of the seven transcription factor binding sites in the promoter of ALKBH2
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or the single transcription factor binding sites within the promoter region of ALKBH3,
would repress transcription factor binding and possibly gene expression. Because data on
the function of ALKBH promoters are less abundant compared to those available for the
MGMT promoter, examination of the promoter function for those genes is an area that
would benefit from further investigation.
6.2. Links to cancer
Dysregulation of numerous DNA repair pathways are involved in tumor development, pro‐
gression, diagnosis, treatment and prognosis, including direct DNA repair proteins [82, 159,
172-179]. Over-expression of direct repair proteins is generally associated with a protective
effect against cell death that would otherwise be induced by alkylating agent treatment.
However, down-regulation or silencing of direct repair protein expression is associated with
increased mutagenesis that precedes tumorgenesis. Therefore expression profiles could be
used to predict potential resistance or enhanced sensitivity to therapeutics.
MGMT has  been  implicated  in  many types  of  human tumors.  Numerous  MGMT  poly‐
morphisms  have  risk  associations  with  breast,  lung,  colon,  and  head  and  neck  cancers
[63,  82,  180-186].  Decreased MGMT  expression is  also found in glioma,  lymphoma, reti‐
noblastoma, breast  (including triple-negative breast  cancer)  and prostate cancer [82,  138,
187] [188]. Moreover, lack of MGMT is associated with enhanced outcomes using alkylat‐
ing agent therapies [5, 62, 67, 82, 86, 138, 139, 180, 181, 183, 189]. Though MGMT  silenc‐
ing occurs in a variety of tumor types, increased levels have also been observed in non-
Hodgkin lymphoma, myeloma and glioma, as well  as in some colon,  pancreatic,  breast,
and lung cancers [63, 183, 184].
Mutations in ALKBH2 and 3 have been associated with an enhanced expression of these pro‐
teins in glioma cells and pediatric brain tumors [171, 190]. Similarly, over-expression of
ALKBH3 has been associated with human rectal carcinoma [191] and prostate cancer, as well
as, lung adenocarcinoma and non-small-cell lung cancer [134] [192]. On the contrary, down
regulation of ALKBH2 has been observed in gastric cancer, promoting growth of gastric can‐
cer cells [193]. Although down regulation of ALKBH2 in gastric cancer cells caused increased
proliferation, ALKBH2 silencing in H1299 lung cancer cells had the opposite effect, increas‐
ing cisplatin sensitivity. Similarly, ALKBH3 silencing induced senescence and sensitivity to
alkylating agents in human adenocarcinoma and prostate cancer cells [134, 193]. Therefore,
further study of the role of ALKBH2 and 3 in both normal and tumor cells is necessary to
elucidate their biological role(s).
6.3. Therapeutic targets
Understanding the mechanism of proteins involved in various DNA repair pathways is cru‐
cial for developing new chemotherapeutic targets and eventually new drugs. DNA alkylat‐
ing agents and ionizing radiation (IR) are often used as chemotherapeutic treatments
because of ability to control the dose administered and area of treatment, as well as the ma‐
jor cytotoxic effects of both agents at high doses. However, in addition to generation of cyto‐
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toxic adducts that cause apoptosis, alkylating agents and IR also form adducts that can be
mutagenic and as a result can cause initiation of secondary cancers. Although DNA repair
deficiencies are associated with increased cancer risk and formation, cancer cells proficient
in DNA repair can reduce therapeutic efficacy. Currently, combination cancer treatment reg‐
imens are being explored that utilize chemotherapy or IR and target specific DNA repair
proteins with pharmacological agents to enhance treatment efficacy and eliminate resistance
to treatment regimens exhibited in some patients [189].
6.3.1. MGMT
Chemotherapeutic drugs such as temozolamide (TMZ) and bis-(2-chloroethyl)-nitrosourea
(BCNU)  generate  some  lesions  repaired  via  the  direct  methyltransferase  mechanism.
Combination treatment with MGMT inhibitors prevents repair and resistance to methyl‐
ating and chloroethylating agents [1, 38, 137] and has also been shown to reverse cispla‐
tin drug resistance [194].
Understanding cellular regulation of MGMT expression will allow for selective down regu‐
lation and sensitization of tumors to alkylating agent chemotherapies. Studies have evaluat‐
ed manipulation of MGMT expression and protein levels. Initial experiments evaluating
MGMT inhibitors identified O6-benzyl guanine (BG) as an efficacious inhibitor of MGMT ac‐
tivity, a single, micromolar dose depleting greater than 99% of MGMT activity in human
cells for 24-hours following drug removal [195]. Moreover, treatment with BG lacks any mu‐
tagenic or cytotoxic effects [195-197]. Clinical trials combining BG and BCNU treatment
have been conducted in colon cancer, sarcoma, melanoma and myeloma, as well as studies
evaluating combination of BG and TMZ [138]. Since synthesis of BG, additional BG-like in‐
hibitors have been developed [196], including O6-(4-bromothenyl) guanine, which has been
evaluated in patients with glioma [187]. Similarly, targeting of MGMT along with combina‐
tion of platinum drugs, including cis- and carboplatinum [198], as well as topoisomerase I
inhibitors has been investigated in various clinical trials [86].
Another approach to regulate MGMT that holds great, essentially untapped therapeutic po‐
tential is strategies utilizing RNA interference-mediated gene silencing to target MGMT
[168, 199, 200]. For instance, if anti-sense molecules can specifically target MGMT mRNA
translation, and degradation is also inhibited, depletion of MGMT is sustainable for long pe‐
riods of time [62]. As seen in glioblastoma patients, expression levels of various miRNA
markers correlate with prognosis [168, 199, 200]. Therefore, one potential new treatment
could use miRNAs, such as miR-181d, to decrease MGMT levels, thus increasing sensitivity
to alkylating agents [168]. Similarly, targeting regions of the MGMT promoter that is accessi‐
ble to transcription factors could interfere with binding and down-regulate MGMT tran‐
scription. However, non-specific targeting of MGMT inhibitors in all cells increases
chemotherapeutic toxicity. Therefore, mutant forms of MGMT that are resistant to BG-like
inhibitors are also being evaluated to limit myelosuppression, affording hematopoietic pro‐
genitor cells protection from BG and BCNU or temozolomide treatment [201-204].
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6.3.2. Alkbh homologs
Similar to MGMT, the role of ALKBH2 and ALKBH3 in repair of DNA alkylation damage at
base-pairing sites is anti-carcinogenic. However, investigations indicate that over-expression
of ALKBH proteins in various cancer cell lines shields those cells against methylating agent
toxicity and would thereby protect against some chemotherapeutic treatments [134, 171,
192]. Additionally, because loss of ALKBH2 and/or ALKBH3 leads to disruption of replica‐
tion, inhibition of ALKBH2 and/or ALKBH3 is a strong target for the development of novel
chemotherapeutic agents. Some specific inhibitors of these proteins have already been iden‐
tified [135, 205, 206], as well as generic α-KG/dioxygenase inhibitors including dimethyl ox‐
alylglycine (DMOG) and α-ketoglutarate derivatives such as oxoglutarate. Studies have
addressed the application of DNA aptamers as inhibitors of ALKBH proteins [207]. Howev‐
er, to date no studies have been conducted in mammalian models that evaluate the combi‐
nation of ALKBH inhibitors with chemotherapeutic alkylating agents.
7. Summary
Direct  repair  proteins  represent  a  unique  class  of  enzymes  that  remove  DNA  damage
without  a  dependence  on  DNA  synthesis.  In  the  future,  better  comprehension  of  how
these proteins function and are produced in cells  will  lead to understanding their  roles
in  formation of  mutations  that  cause  cancer.  Eventually,  that  knowledge will  foster  the
development of drugs to target these proteins and/or to regulate their expression to im‐
prove patient outcomes.
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